-+ 0.00%
-+ 0.00%
-+ 0.00%

Anika Q1 operating loss widens to $5.49 million; revenue rises 13% to $29.6 million

PUBT·04/29/2026 11:15:35
Listen to the news
Anika Q1 operating loss widens to $5.49 million; revenue rises 13% to $29.6 million
  • Anika Therapeutics posts Q1 2026 net loss of $5.1 million, or $(0.37) per diluted share.
  • Revenue rises 13% to $29.6 million, driven by OEM Channel strength and favorable order timing.
  • Adjusted EBITDA improves to $4.3 million from $127,000.
  • Operating expenses increase to $24.5 million, including $4.9 million of one-time severance costs.
  • Maintains 2026 revenue outlook of $114 million-$122.5 million, forecasting adjusted EBITDA at 5%-10% of revenue.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anika Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604290705PRIMZONEFULLFEED9709147) on April 29, 2026, and is solely responsible for the information contained therein.